Novartis : receives European approval for Cosentyx® as first and only IL-17A inhibitor for hidradenitis suppurativa

Cosentyx® is the first new biologic treatment for hidradenitis suppurativa in nearly a decade, offering clinically meaningful results across the most debilitating... | June 1, 2023

Related Keywords

Germany ,Trinidad And Tobago ,United States ,Switzerland ,America ,Trinidad ,Dermatol Venereol ,Haseeb Ahmad ,Julie Masow ,Satoshi Sugimoto ,Hidradenitis Suppurativa ,Mac Mahon ,Richard Jarvis ,Parag Mahanti ,Michael Meo ,Mary Carmichael ,Samir Shah ,Isabella Zinck ,Klinikum Dessau ,Nicole Zinsli Somm ,Novartis Cosentyx ,Sloan Simpson ,Marlena Abdinoor ,Twitter ,Brandenburg Medical School ,Novartis ,Clinical Study Program ,Exchange Commission ,Novartis Europharm ,Novartis Pharmaceuticals Corp ,Drug Administration ,European Hidradenitis Suppurativa Foundation ,European Commission ,Professor Christos ,Founding Professor ,President Europe ,Hidradenitis Suppurativa Clinical Response ,Rev Dis Primers ,Pooled Data ,Pharmaceuticals Corp ,Two Secukinumab Dose Regimens ,Subjects With Moderate ,Severe Hidradenitis Suppurativa ,Provides Sustained Improvements ,Psoriatic Arthritis ,Pooled Safety ,Its Effect ,Health Related Quality ,Patient Reported Outcomes ,Patient Relat Outcome Meas ,Manuels D ,Antoniom L ,Skin Disease ,Related Quality ,Life Rijeka ,Novartis Ag Stock Exchange ,News ,Information ,Press Release ,Us ,The ,First ,Few ,Biologic ,Treatment ,Or ,Hidradenitis ,Suppurativa ,N ,Early ,Offering ,Linically ,Meaningful ,Results ,Cross ,Ost Novn Ch0012005267 ,